NCT04096716 is a Phase 1 clinical trial of Tc-99m tilmanocept in Central Nervous System Neoplasms, sponsored by Washington University School of Medicine.

Who is sponsoring NCT04096716?

NCT04096716 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT04096716?

Interventions in NCT04096716: Tc-99m tilmanocept.

What condition does NCT04096716 study?

NCT04096716 studies Central Nervous System Neoplasms, Central Nervous System Tumor.

Is NCT04096716 still recruiting?

NCT04096716 is currently terminated. Last updated 21 December 2023.

Last reviewed 2023-12-21 · How we verify

NCT04096716

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mapping Draining Lymph Nodes in CNS Malignancies

Terminated Phase 1 Last updated 21 December 2023

What this trial tests

Phase 1 trial testing Tc-99m tilmanocept in Central Nervous System Neoplasms in 14 participants. Terminated before completion.

Timeline

3 December 2019

Primary endpoint
30 April 2022

30 April 2022

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	14
Start date	3 December 2019
Primary completion	30 April 2022
Estimated completion	30 April 2022
Sites	1 location across United States

Drugs / interventions tested

Tc-99m tilmanocept

Conditions studied

Central Nervous System Neoplasms — all drugs for Central Nervous System Neoplasms →
Central Nervous System Tumor — all drugs for Central Nervous System Tumor →

Sponsor

Washington University School of Medicine

Who can join

18 and older, any sex, with Central Nervous System Neoplasms or Central Nervous System Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to determine whether the lymph nodes that drain a brain tumor can be detected by imaging after injection of a substance called Tc-99m tilmanocept directly into the brain tissue around the tumor. Tc-99m tilmanocept is a radioactive substance that is used to find lymph nodes by injecting it and then scanning the body with a device that can trace its radioactivity. In this study, the investigators are looking to see how long it takes the Tc-99m tilmanocept to travel from the tumor to the lymph nodes. The investigators will be using it to map lymph nodes as they relate to specific brain areas.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A pilot study of lymphoscintigraphy with tracer injection into the human brain.
Coxon AT, Desai R, Patel PR, Vellimana AK, et al · · 2023 · cited 2× · PMID 36994857 · DOI 10.1177/0271678x231160891

Verify or expand the search:

Other trials of Tc-99m tilmanocept

Trials testing the same drug.

NCT04663126 — Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma · EARLY_PHASE1 · terminated

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04096716 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 21 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04096716.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing